MERIDIAN BIOSCIENCE, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 16 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-11-05: Reporting owner WELTZIEN LOURDES; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-11-05: Reporting owner Serafini-Lamanna Tony; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-11-05: Reporting owner Kenny John P.; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-11-05: Reporting owner Baldasare Bryan T; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-11-05 | WELTZIEN LOURDES Officer (EVP, Life Science) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,107 12,107 owned after | $18.48 exercise price | 2020-11-09 | |
| 2020-11-05 | Serafini-Lamanna Tony Officer (Executive VP-Diagnostics) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,107 12,107 owned after | $18.48 exercise price | 2020-11-09 | |
| 2020-11-05 | Kenny John P. Director, Officer (Chief Executive Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +83,535 83,535 owned after | $18.48 exercise price | 2020-11-09 | |
| 2020-11-05 | Baldasare Bryan T Officer (Exec VP & CFO) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,107 12,107 owned after | $18.48 exercise price | 2020-11-09 | |
| 2020-07-28 | Bihl Anthony P III Director | 4/A | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,595 4,595 owned after | $23.50 exercise price | 2020-08-12 | |
| 2020-07-28 | Bihl Anthony P III Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,595 4,595 owned after | $8.71 exercise price | 2020-07-29 | |
| 2020-06-30 | Baldasare Bryan T Officer (Exec VP & CFO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 0 owned after | $19.71 exercise price | 2020-07-02 | |
| 2020-05-21 holding as of filing | Serafini-Lamanna Tony Officer (Executive VP-Diagnostics) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $14.60 exercise price | 2020-05-21 | ||
| 2020-05-21 holding as of filing | Serafini-Lamanna Tony Officer (Executive VP-Diagnostics) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.97 exercise price | 2020-05-21 | ||
| 2020-01-29 | Williams Felicia Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,205 17,205 owned after | $10.46 exercise price | 2020-01-31 | |
| 2020-01-29 | Sazdanoff Catherine Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,205 17,205 owned after | $10.46 exercise price | 2020-01-31 | |
| 2020-01-29 | Rice John McCune Jr. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,205 17,205 owned after | $10.46 exercise price | 2020-01-31 | |
| 2020-01-29 | PHILLIPS DAVID Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,205 17,205 owned after | $10.46 exercise price | 2020-01-31 | |
| 2020-01-29 | McIlwraith John Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,205 17,205 owned after | $10.46 exercise price | 2020-01-31 | |
| 2020-01-29 | Ellingwood Dwight E Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,205 17,205 owned after | $10.46 exercise price | 2020-01-31 | |
| 2020-01-29 | Anderson James M. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,205 17,205 owned after | $10.46 exercise price | 2020-01-31 |